The findings we report here compliment those reported by Wysocka et al. [6], in which the beneficial effects of CpG and IL-15 were observed following the treatment of human NK and CD8+ T cells isolated from patients with cutaneous T-cell lymphoma. The gene discussed is IL15; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.